Browsing by Author Hamilton, Anne

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 18 of 18
Issue DateTitleAuthor(s)Citation
2005The aromatase inhibitors in early breast cancer: who, when, and why?Hamilton, Anne; Nordman, I; Spillane, Andrew; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: SurgeryThe aromatase inhibitors in early breast cancer: who, when, and why?, Medical Journal of Australia, vol.183,(1),2005,pp 24-27
2010Cetuximab is Associated with Excessive Toxicity when Combined with Bevacizumab Plus mFOLFOX6 in Metastatic Colorectal CarcinomaChen, Helen X.; Hamilton, Anne; Horvath, Lisa; Christos, Paul; Kindler, Hedy L.; Matulich, Daniel; Ocean, Allyson; Polite, Blase; Sparano, Joseph A; Medicine; Central Clinical School: Medicine; Central Clinical School: MedicineCetuximab is Associated with Excessive Toxicity when Combined with Bevacizumab Plus mFOLFOX6 in Metastatic Colorectal Carcinoma, Clinical Colorectal Cancer, vol.9, 5,pp 290-296
2005Chemotherapy: what progress in the last 5 years?Hamilton, Anne; Hortobagyi, Gabriel; Central Clinical School: MedicineChemotherapy: what progress in the last 5 years?, JOURNAL OF CLINICAL ONCOLOGY 2005, vol.23,(8),2005,pp 1760-1775
2010Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KITHamilton, Anne; Dobrovic, Alexander; Handolias, D; Kerr, L; McArthur, Grant A.; Moodie, K; Salemi, R; Tan, A; Central Clinical School: MedicineClinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT, British Journal of Cancer, vol.102, 8,pp 1219-1223
2014Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanomaCarlino, Matteo; Hamilton, Anne; Haydu, Lauren; Kakavand, Hojabr; Kefford, Richard (Rick); Long, Georgina; Menzies, Alexander Maxwel; O'Toole, Sandra; Scolyer, Richard; Thompson, John; Yu, Bing; Cooper, Wendy; Ng, C; Western Clinical School: Medicine (Westmead); Central Clinical School: Medicine; Central Clinical School: Surgery; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: Medicine; Central Clinical School: Pathology; Central Clinical School: Pathology; Central Clinical School: Surgery; Central Clinical School: MedicineCorrelation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma, British Journal of Cancer, vol.111, 2, 2014,pp 292-299
2011Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group StudyHamilton, Anne; Davies, Angela; Egorin, Merrill; et al, various; Leal, Ticiana; Lenz, Heinz-Josef; LoRusso, Patricia; Mier, James; Ramanathan, Ramesh; Remick, Scot; Sarantopoulos, John; Shibata, Stephen; Takimoto, Chris; Central Clinical School: MedicineDose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study, Cancer Chemotherapy and Pharmacology, vol.68, 6, 2011,pp 1439-1447
2010High Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtypeHamilton, Anne; Lee, Cheok; McNeil, Catriona; Spillane, Andrew; Crea, P; Lopez-Knowles, Elena; McLeod, Duncan; Millar, Ewan; Morey, Adrienne; Murphy, N C; Musgrove, Elizabeth A.; Oakes, Samantha; Ormandy, Christopher J.; O'Toole, Sandra; Pinese, Mark; Qiu, Min; Sutherland, Robert L.; Zardawi, Ibrahim; Zardawi, Sarah J; Central Clinical School: Medicine; Central Clinical School: Medicine; Western Clinical School: Medicine (Westmead); Northern Clinical School: MedicineHigh Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtype, Histopathology, vol.56, 3,pp 286-296
2013Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancerBeith, Jane; Clarke, Stephen; Dhillon, Haryana; McLachlan, Andrew; Olesen, Inger; Rittau, Anneliese; Vardy, Janette; Beale, Phillip; Hamilton, Anne; Leslie, Felicity; Sullivan, Anne; Warby, Anne; Central Clinical School: Medicine; Concord Clinical School: Medicine; Central Clinical School: Medicine; Pharmacy; Northern Clinical School: Kolling Institute; Pharmacy; Concord Clinical School: MedicineInvestigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer, SpringerPlus, vol.2, 1, 2013,pp 1-5
2009LHRH agonists for adjuvant therapy of early breast cancer in premenopausal womenHamilton, Anne; Beith, Jane M.; Goel, Shom; Sharma, Rohini; Central Clinical School: MedicineLHRH agonists for adjuvant therapy of early breast cancer in premenopausal women, Cochrane Database of Systematic Reviews, vol.4, 4,pp Article number CD004562-N/A
2008LHRH agonists for adjuvant therapy of early breast cancer in premenopausal womenHamilton, Anne; Beith, Jane M.; Sharma, Rohini; Central Clinical School: MedicineLHRH agonists for adjuvant therapy of early breast cancer in premenopausal women, Cochrane Database of Systematic Reviews, vol.4,(CD004562),2008,pp DOI:10.1002/14651858.CD004562.pub3.-N/A
2008MelanomaHamilton, Anne; Clark, Katherine; Central Clinical School: MedicineMelanoma in Prognosis in Advanced Cancer, Oxford University Press, 2008, pp. 257-265
2012Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432Hamilton, Anne; Dowlati, Afshin; et al, Various; LoRusso, Patricia; Mani, Sridar; Mulkerin, Daniel; Ramanathan, Ramesh; Rudek, Michelle; Sarantopoulos, John; Shibata, Stephen; Takimoto, Chris; Venkatakrishnan, Karthik; Central Clinical School: MedicinePharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432, Clinical Cancer Research, vol.18, 10, 2012,pp 2954-2963
2010A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue CorrelatesHamilton, Anne; Buckley, Michael; Christos, Paul; Goldberg, Lauren; Liebes, Leonard; Min, Christina; Osman, Iman; Ott, Patrick; Pavlick, Anna C.; Polsky, David; Safarzadeh-Amiri, Sara; Wright, John J.; Yee, Herman; Yoon, Joanne; Central Clinical School: MedicineA Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates, PLoS One, vol.5, 12,pp e15588 - 1-e15588 - 9
2010A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanomaHamilton, Anne; Christos, Paul; Doyle, Austin; Haas, Naomi; Jones, Amanda; Liddell, Sandra; Millward, Michael; Muggia, Franco; Ott, Patrick; Pavlick, Anna C.; Shore, Tsiporah; Central Clinical School: MedicineA phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma, PLoS One, vol.5, 1,pp e8714-1-e8714-7
2011Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic MelanomaHamilton, Anne; Haydu, Lauren; Hughes, Thomas; Kefford, Richard (Rick); Long, Georgina; Mann, Graham; Scolyer, Richard; Thompson, John; Menzies, Alexander; Nagrial, Adnan; Central Clinical School: Medicine; Central Clinical School: Surgery; Melanoma Foundation; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Western Clinical School: Westmead Millennium Institute; Central Clinical School: Pathology; Central Clinical School: SurgeryPrognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma, Journal of Clinical Oncology, vol.29, 10, 2011,pp 1239-1246
2010Results of a Multicenter, Randomized, Double-Blind Phase 2/3 Study of Lenalidomide in the Treatment of Pretreated Relapsed or Refractory Metastatic Malignant MelanomaHamilton, Anne; Eisen, Tim; Glaspy, John; Hersey, Peter; Jungnelius, Jarl; Knight, Robert; Millward, Michael; Trefzer, Uwe; Central Clinical School: MedicineResults of a Multicenter, Randomized, Double-Blind Phase 2/3 Study of Lenalidomide in the Treatment of Pretreated Relapsed or Refractory Metastatic Malignant Melanoma, Cancer, vol.116, 1,pp 146-154
2005Systematic review of LHRH agonists for the adjuvant treatment of early breast cancer.Beith, Jane; Hamilton, Anne; Sharma, Rohini; Central Clinical School: Medicine; Central Clinical School: Medicine; Western Clinical School: Westmead Millennium InstituteSystematic review of LHRH agonists for the adjuvant treatment of early breast cancer., Breast, vol.14,(3),2005,pp 181-191
2004Systematic Review Of Taxane-Containing Versus Non-Taxane-Containing Regimens For Adjuvant And Neoadjuvant Treatment Of Early Breast Cancer.Ghersi, Davina; Hamilton, Anne; Nowak, Anna; Stockler, Martin; Wilcken, Nicholas; School of Public Health: NH&MRC Clinical Trials Centre; Central Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Western Clinical School: Medicine (Westmead)Systematic Review Of Taxane-Containing Versus Non-Taxane-Containing Regimens For Adjuvant And Neoadjuvant Treatment Of Early Breast Cancer., Lancet Oncology, vol.5,(6),2004,pp 372-380